1Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries I isolation and characterization. Eur J Biochem, 1972; 28:334 - 339.
2Morgenthaler NG, Struck J, Monso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006; 52: 112 - 119.
3Nagy G, Mulchahey JJ, Smyth DG et al. The glycopeptide moiety of vasopressinneurophysin precursor is neurohypophy- sial prolactin releasing factor. Biochem Biophys Res Com- mun, 1988; 151:524 -529.
4Barat C, Simpson L, Breslow E. Properties of human vaso- pressin precursor constructs: Inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry, 2004 ; 43 : 8191 - 8203.
5Dtmser MW, Wenzel V, Mayr AJ et al. Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs, 2003; 63:237 -256.
6Garofeanu CG, Weir M, Rosas - Arellano MP et al. Causes of reversible nephrogenic diabetes insipidus : a systematic review. Am J Kidney Dis, 2005 ; 45 : 626 - 637.
7Griebel G, Stemmelin J, Gal CS et al. Non - peptide vaso- pressin Vlb receptor antagonists as potential drugs for the treatment of stress - related disorders. Curr Pharm Des, 2005; 11:1549 - 1559.
8Preibisz JJ, Sealey JE, Laragh JH et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hvoertension, 1983 : 5 : 1129 - 1138.
9Morgenthaler NG, Struck J, the measurement of copeptin, Bergmann A et al. Assay for a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006; 52 ( 1 ) 112.
10Katan M, Morgenthaler NG, Dixit KC et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. Clin Endocrinol Metab, 2007 ; 92 : 2640 - 2643.
5Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.Veterans Afairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group[J].N Engl J Med,1999,341(6):410-418.
6Kazi D,Farmer JA.Raising high-density lipoprotein cholesterol:innovative strategies against an old adversary[J].Curt Atheroseler Rep,2005,7(2):88-94.
8Walldius G,Jungner I,Aastveit AH,et al.The apoB/apoA-Ⅰ ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk[J].Clin Chem Lab Med,2004,42(12):1355-1363.
9van der Steeg WA,Boekholdt SM,Stein EA,et al.Role of the apolipoprotein B-apolipoprotein A-Ⅰ ratio in cardiovascular risk assessment:a case-control analysis in EPIC-Norfolk[J].Ann Intern Med,2007,146(9):640-648.
10Meisinger C,Loewel H,Mraz W,et al.Prognostic value of apolipoprotein B and A-Ⅰ in the prediction of myocardial infarction in middle-aged men and women:results from the MONICA/KORA Augsburg cohort study[J].Eur Heart J,2005,26(3):271-278.
